Literature DB >> 28378342

Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis.

H Cramer1,2, M Schäfer1,3, M Schöls1,3,4, J Köcke1,3, S Elsenbruch4, R Lauche1,2, H Engler4, G Dobos1, J Langhorst1,3.   

Abstract

BACKGROUND: Perceived stress seems to be a risk factor for exacerbation of ulcerative colitis. Yoga has been shown to reduce perceived stress. AIMS: To assess the efficacy and safety of yoga for improving quality of life in patients with ulcerative colitis.
METHODS: A total of 77 patients (75% women; 45.5 ± 11.9 years) with ulcerative colitis in clinical remission but impaired quality of life were randomly assigned to yoga (12 supervised weekly sessions of 90 min; n = 39) or written self-care advice (n = 38). Primary outcome was disease-specific quality of life (Inflammatory Bowel Disease Questionnaire). Secondary outcomes included disease activity (Rachmilewitz clinical activity index) and safety. Outcomes were assessed at weeks 12 and 24 by blinded outcome assessors.
RESULTS: The yoga group had significantly higher disease-specific quality of life compared to the self-care group after 12 weeks (Δ = 14.6; 95% confidence interval=2.6-26.7; P = 0.018) and after 24 weeks (Δ = 16.4; 95% confidence interval=2.5-30.3; P = 0.022). Twenty-one and 12 patients in the yoga group and in the self-care group, respectively, reached a clinical relevant increase in quality of life at week 12 (P = 0.048); and 27 and 17 patients at week 24 (P = 0.030). Disease activity was lower in the yoga group compared to the self-care group after 24 weeks (Δ = -1.2; 95% confidence interval=-0.1-[-2.3]; P = 0.029). Three and one patient in the yoga group and in the self-care group, respectively, experienced serious adverse events (P = 0.317); and seven and eight patients experienced nonserious adverse events (P = 0.731).
CONCLUSIONS: Yoga can be considered as a safe and effective ancillary intervention for patients with ulcerative colitis and impaired quality of life. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02043600.
© 2017 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2017        PMID: 28378342     DOI: 10.1111/apt.14062

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease.

Authors:  Steven C Lin; Adam S Cheifetz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-07

Review 2.  The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastrointestinal Tract.

Authors:  Bruno Bonaz; Valérie Sinniger; Sonia Pellissier
Journal:  Front Immunol       Date:  2017-11-02       Impact factor: 7.561

Review 3.  Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders.

Authors:  Sigrid Breit; Aleksandra Kupferberg; Gerhard Rogler; Gregor Hasler
Journal:  Front Psychiatry       Date:  2018-03-13       Impact factor: 4.157

Review 4.  Stress Triggers Flare of Inflammatory Bowel Disease in Children and Adults.

Authors:  Yue Sun; Lu Li; Runxiang Xie; Bangmao Wang; Kui Jiang; Hailong Cao
Journal:  Front Pediatr       Date:  2019-10-24       Impact factor: 3.418

5.  Subjective Psychophysical Experiences in the Course of Inflammatory Bowel Disease-A Comparative Analysis Based on the Polish Pediatric Crohn's and Colitis Cohort (POCOCO).

Authors:  Aleksandra Glapa-Nowak; Anna Bukowska-Posadzy; Mariusz Szczepanik; Jarosław Kwiecień; Anna Szaflarska-Popławska; Barbara Iwańczak; Anna Flak-Wancerz; Łukasz Dembiński; Marcin Osiecki; Jarosław Kierkuś; Tomasz Banasiewicz; Harald Walach; Aleksandra Banaszkiewicz; Jarosław Walkowiak
Journal:  Int J Environ Res Public Health       Date:  2021-01-18       Impact factor: 3.390

6.  Multimodal stress reduction and lifestyle modification program for patients with ulcerative colitis: a qualitative study.

Authors:  Christoph Schlee; Christine Uecker; Nina Bauer; Anna K Koch; Jost Langhorst
Journal:  BMC Complement Med Ther       Date:  2022-03-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.